Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

These results imply that M + P is superior for patients with an intrinsically good prognosis and inferior for those patients with a poor prognosis. If reliable prognostic factors can be established for this disease, they could be used to select therapy for individual patients.